Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today announced the launch of the ddPCR™ Supermix for Residual DNA Quantification. When used with Bio-Rad’s Droplet Digital™ PCR Systems, this supermix provides a highly precise and sensitive method for directly measuring host cell DNA (HCD) that contaminates biopharmaceutical products.
To manufacture therapeutic proteins, vaccines, and other biologics, pharmaceutical companies must purify the active molecules from the bacterial or mammalian host cells in which they were produced. However, due to inefficiencies in this process, host cell impurities — including DNA — routinely contaminate the product. Manufacturers must ensure that HCD levels in the final drug product fall within U.S. Food and Drug Administration and World Health Organization guidelines.
Quality control analysts typically measure residual HCD using quantitative real-time PCR (qPCR), a process that requires purification of HCD to remove PCR inhibitors from the sample. Not only does this step add time and cost,...
Direct Quantification Using Droplet Digital PCR Technology
Using ddPCR technology and Bio-Rad’s new supermix, researchers can eliminate the DNA extraction step and directly measure residual HCD. This is possible because reaction partitioning and end-point analysis make Droplet Digital PCR less susceptible to PCR inhibition than qPCR.
ddPCR technology also simplifies HCD quantification by eliminating the need for a standard curve for determining target DNA concentration because it allows direct counting of the number of target molecules. Each lot of ddPCR Supermix for Residual DNA Quantification is produced under strict quality control to ensure low background of E. coli, mouse, human, yeast, and CHO cell DNA.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) develops, manufactures, and markets a broad range of innovative products and solutions for the life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and healthcare industry customers through its global network of operations. The company employs more than 7,600 people worldwide and had revenues exceeding $2.1 billion in 2014. For more information, please visit www.bio-rad.com.